- Home
- SOTK vs UNCY Comparison
SOTK vs UNCY Comparison
Compare SOTK & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOTK | UNCY |
|---|---|---|
| Founded | 1975 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.7M | 141.8M |
| IPO Year | 1987 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SOTK | UNCY |
|---|---|---|
| Price | $4.06 | $6.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 26.6K | ★ 488.8K |
| Earning Date | 01-13-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $20,420,804.00 | N/A |
| Revenue This Year | $2.67 | N/A |
| Revenue Next Year | $8.20 | N/A |
| P/E Ratio | $40.80 | ★ N/A |
| Revenue Growth | ★ 1.34 | N/A |
| 52 Week Low | $3.23 | $3.71 |
| 52 Week High | $5.15 | $11.00 |
Technical Indicators
Market Signals| Indicator | SOTK | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 62.26 |
| Support Level | $3.87 | $6.01 |
| Resistance Level | $4.38 | $7.19 |
| Average True Range (ATR) | 0.25 | 0.47 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 39.46 | 85.89 |
Price Performance
Historical ComparisonAbout SOTK Sono-Tek Corporation
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.